Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

LAG3 (Lymphocyte Activating 3)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

Immunoscore® TCE test

LAG-3 IHC assay

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

Immunoscore® TCE test

LAG-3 IHC assay

›

High 4-gene inflammatory score	Mesothelioma	High 4-gene inflammatory score	Mesothelioma	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
LAG3 expression	Melanoma	LAG3 expression	Melanoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
LAG3 expression	Melanoma	LAG3 expression	Melanoma	nivolumab/relatlimab-rmbw Sensitive: B - Late Trials nivolumab / relatlimab-rmbw Sensitive : B	nivolumab/relatlimab-rmbw Sensitive: B - Late Trials nivolumab / relatlimab-rmbw Sensitive : B
LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
PD-L1 overexpression + LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	PD-L1 overexpression + LAG3 expression + CTAG1B expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
LAG3 overexpression	Diffuse Large B Cell Lymphoma	LAG3 overexpression	Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3	MGD013 Sensitive: C3 – Early Trials MGD013 Sensitive : C3
IFNG 4-genes signature	Non Small Cell Lung Cancer	IFNG 4-genes signature	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG 4-genes signature	Urothelial Cancer	IFNG 4-genes signature	Urothelial Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
LAG3 overexpression	Soft Tissue Sarcoma	LAG3 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
LAG3 expression	Gastric Cancer	LAG3 expression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LAG3 expression	Renal Cell Carcinoma	LAG3 expression	Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
LAG3 overexpression	Melanoma	LAG3 overexpression	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3